Release Summary

Millendo Licenses Phase 2 Polycystic Ovary Syndrome (PCOS) Drug Candidate from AstraZeneca and Secures Series B Financing of $62 Million to Advance Pipeline of Endocrine Disorder Therapies

Millendo Therapeutics, Inc.